Related Experiment Videos
Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences
K T Kivistö1, P J Neuvonen, U Klotz
1Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
Clinical Pharmacokinetics
|July 1, 1994
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients.
Scandinavian journal of pain·2018
Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans.
Clinical pharmacology and therapeutics·2015
Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.
Clinical pharmacology and therapeutics·2014
Grapefruit juice inhibits the metabolic activation of clopidogrel.
Clinical pharmacology and therapeutics·2013
A mechanistic, model-based approach to safety assessment in clinical development.
CPT: pharmacometrics & systems pharmacology·2013
Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.
Clinical pharmacology and therapeutics·2013
Clinical Pharmacokinetics of Polmacoxib (CG100649): A Tissue-Selective Dual COX-2 and Carbonic Anhydrase I/II Inhibitor.
Clinical pharmacokinetics·2026
Efsubaglutide Alfa: A Comprehensive Pharmacological Review.
Clinical pharmacokinetics·2026
Application of Pharmacometric Modelling Towards Precise Dosing in Neonates, Infants and Toddlers: A Scoping Review.
Clinical pharmacokinetics·2026
Current perspectives in the pharmacological management of cutaneous and mucosal leishmaniasis.
Expert opinion on pharmacotherapy·2026
New potassium binders: we need them-we do not need them.
Clinical kidney journal·2026
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity.
Diabetes, obesity, and cardiometabolic CARE·2026
Ibogaine for Substance Use Disorders.
Advances in therapy·2026